These so-called non-oncogene addictions [6] or collateral sensitivities [40] in cancer cells have been shown to be viable therapeutic strategies for the killing of tumor cells with non-targetable oncogenes (e.g. MYC) [10] or those that have gained resistance to targeted therapy [13, 40]. The gene discussed is MYC; the disease is neoplasm.